TVRD – tvardi therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by analysts at Lucid Cap Mkts from a "hold" rating to a "strong-buy" rating.
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights [Yahoo! Finance]
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights
Form 4 Tvardi Therapeutics, For: Jan 29 Filed by: O'Brien Stephen Paul
Form 4 Tvardi Therapeutics, For: Jan 29 Filed by: Conn Avi Daniel
Form 4 Tvardi Therapeutics, For: Jan 29 Filed by: Alibhai Imran Nizamudin
Form 4 Tvardi Therapeutics, For: Jan 29 Filed by: Kauh John Saewook M.D.
Form 8-K Tvardi Therapeutics, For: Jan 16
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.